drugset / Trial / NCT07836023
PFAS Clinical Trial
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate whether treatment with cholestyramine for either one, two, three, or four months (up to 120 days), meaningfully influences per- and polyfluoroalkyl substances (PFAS) removal from the body.
Timeline
- Start
- 2026-11
- Primary completion
- 2030-06
- Completion
- 2030-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cholestyramine | Other / unclassified | 12 g | — |
| Background | Centrum | Unknown | — | — |
Indications
No indication recorded.